Antisoma zu alten Höhen ?
| eröffnet am: | 31.10.06 09:14 von: | DonCarlo |
| neuester Beitrag: | 25.04.21 01:33 von: | Tanjauqtwa |
| Anzahl Beiträge: | 994 | |
| Leser gesamt: | 183107 | |
| davon Heute: | 8 | |
bewertet mit 10 Sternen |
||
|
|
||
02.10.10 14:36
#651
HerrNachbar
die angestellten nehmen aktien
http://www.investegate.co.uk/Article.aspx?id=20101001140200H8371
gutes zeichen. vielleicht ja auch konstruiert.
gutes zeichen. vielleicht ja auch konstruiert.
05.10.10 06:45
#652
hoomer
Biotech off the critical list
"... Meanwhile nervousness has left many biotech/pharma companies trading at almost level with their cash piles - Vernalis, Antisoma, Phytopharm, Vectura and Renovo, to name but a few. These firms have either suffered a clinical or commercial setback, like Antisoma and Vectura. Or they are now so early-stage in terms of their development that investors do not want to chase risk, with Vernalis an obvious example. The lack of share price appreciation must be particularly galling for Phytopharm, as the company was one of the few to raise significant amounts of money during the recession, nearly £25m to fund the development of its Parkinson's treatment, Cogane..."
http://www.investorschronicle.co.uk/...tech-off-the-critical-list.jsp
http://www.investorschronicle.co.uk/...tech-off-the-critical-list.jsp
08.10.10 18:28
#657
kalleari
@Lamaro
Text nix Neues
Weiter hoffen, daß nicht wieder Rohrkreppierer. aus der Pipeline im Frühjahr kommt.
Mfg
Kalle
Weiter hoffen, daß nicht wieder Rohrkreppierer. aus der Pipeline im Frühjahr kommt.
Mfg
Kalle
12.10.10 16:41
#660
kalle50
Du bist vielleicht ein Optimist
investiere mal maximal 500 Euro und hoffe das es irgendwann mal nach oben geht.Mein Einstieg damals war 2000 Stck bei 2,60 Euro für 5200Euro. Jetzt rechne mal wieviel ich kaufen müßte selbst wen der Kurs von heute um 1000% steigt um wieder auf mein Geld zu kommen.Da bleibt dir sicher die Spucke weck.Gruß Kalle 50!
12.10.10 17:30
#661
lamaro
das war vor
8 jahren als du gekauft hast ....sollte das präp. was in phase drei ist kommen geht der kurs nach oben.
Klar wirst du Deinen Verlust nicht mehr reinholen..tut mir Leid für Dich. Nur ich bin zu einem anderen
Kurs eingestiegen wie Du.
13.10.10 09:56
#662
silverfish
In 6 Monaten wissen wir mehr...
Antisoma Interim Management Statement
08:05 13.10.10
London, UK, and Cambridge, MA: 13 October 2010 - Cancer drug developer Antisoma
plc (LSE: ASM; USOTC: ATSMY) today publishes its Interim Management Statement
for the period from 1 July to 12 October 2010.
Antisoma's CEO, Glyn Edwards, said: "We are on track to report pivotal trial
results for AS1413 in the first half of next year. If these are positive, we
will file marketing applications. Our latest market research suggests that
AS1413 could generate very substantial sales revenues."
Highlights
AS1413
* New market research indicates potential sales of up to $670 million per
annum in acute myeloid leukaemia (AML)
* Phase III trial in secondary AML fully enrolled
* Phase III trial results expected H1 2011
AS1411
* Phase IIb trial in AML ongoing, extended to India
* Phase IIb data expected H1 2011
Joint Chairman and CEO's statement
We will soon report data from two important clinical trials: a phase III study
of AS1413 and a phase IIb study of AS1411. The AS1413 trial is most critical
because positive data would lead to submissions for marketing authorisations.
AS1413 in the spotlight
In September we announced that we had completed the enrolment of over 420
patients into 'ACCEDE', a pivotal phase III trial evaluating AS1413 as a
treatment for secondary AML. This put us on track to report the trial's outcome
in H1 2011. Collection and collation of data remains on course for that timing.
ACCEDE is the biggest randomised trial conducted to date in secondary AML.
We have recently completed a large market research and forecasting exercise to
evaluate the revenues that could be achieved following launches of AS1413. This
focused mainly on the opportunity in the U.S., but has also served to refine our
view of potential sales in other markets. The exercise included an analysis of
all claims made under the U.S. Medicare system for the treatment of AML during
2008 and a survey of 150 U.S. oncologists and haematologists who treat AML
patients.
Our forecasts based on this research indicate that peak global sales of AS1413
could reach $670 million per annum if we gain initial approvals for treatment of
patients with secondary AML and subsequent approvals for use in older 'de novo'
AML patients. With approvals in secondary AML alone, we could expect global peak
sales in the range of $440 to $580 million.
We continue to talk to potential licensing partners for AS1413. There is
interest in global and regional partnerships. However, we will only conclude a
deal or deals before phase III data if compelling terms are available.
AS1411 also approaching key results
We are enrolling patients into a phase IIb trial of AS1411 in AML, which builds
on positive findings from an earlier phase II trial in the same setting. We
recently expanded the geographical reach of the study to include India in
addition to sites already active in the U.S., South Korea, Taiwan, Australia and
New Zealand.
We expect to report headline findings from the phase IIb trial in the first half
of 2011. If these are positive, the next step will be a pivotal phase III trial
in AML, as well as consideration of opportunities for the drug in other cancer
settings. Clinical and non-clinical data suggest that AS1411 could have
application across a number of blood cancers and solid tumours.
DCAM programme progressing towards partnering
Our DCAMs (dendritic cell auto-immune modulators) are highly specific, small-
molecule inhibitors of wild-type Flt3 designed for oral treatment of auto-immune
conditions. Following positive results in animal models of inflammatory bowel
disease and rheumatoid arthritis, we are working towards establishing a
licensing partnership for further development of the programme.
Cash resources meet business needs
Our existing cash resources are anticipated to cover the needs of the business
until well after we report our critical trial data in the first half of calendar
2011.
Outlook
Our current focus is delivery of the clinical data for AS1413 and AS1411 and
preparation to ensure we can move rapidly to exploit positive outcomes from the
trials of either or both of these drugs.
Barry Price
Chairman
08:05 13.10.10
London, UK, and Cambridge, MA: 13 October 2010 - Cancer drug developer Antisoma
plc (LSE: ASM; USOTC: ATSMY) today publishes its Interim Management Statement
for the period from 1 July to 12 October 2010.
Antisoma's CEO, Glyn Edwards, said: "We are on track to report pivotal trial
results for AS1413 in the first half of next year. If these are positive, we
will file marketing applications. Our latest market research suggests that
AS1413 could generate very substantial sales revenues."
Highlights
AS1413
* New market research indicates potential sales of up to $670 million per
annum in acute myeloid leukaemia (AML)
* Phase III trial in secondary AML fully enrolled
* Phase III trial results expected H1 2011
AS1411
* Phase IIb trial in AML ongoing, extended to India
* Phase IIb data expected H1 2011
Joint Chairman and CEO's statement
We will soon report data from two important clinical trials: a phase III study
of AS1413 and a phase IIb study of AS1411. The AS1413 trial is most critical
because positive data would lead to submissions for marketing authorisations.
AS1413 in the spotlight
In September we announced that we had completed the enrolment of over 420
patients into 'ACCEDE', a pivotal phase III trial evaluating AS1413 as a
treatment for secondary AML. This put us on track to report the trial's outcome
in H1 2011. Collection and collation of data remains on course for that timing.
ACCEDE is the biggest randomised trial conducted to date in secondary AML.
We have recently completed a large market research and forecasting exercise to
evaluate the revenues that could be achieved following launches of AS1413. This
focused mainly on the opportunity in the U.S., but has also served to refine our
view of potential sales in other markets. The exercise included an analysis of
all claims made under the U.S. Medicare system for the treatment of AML during
2008 and a survey of 150 U.S. oncologists and haematologists who treat AML
patients.
Our forecasts based on this research indicate that peak global sales of AS1413
could reach $670 million per annum if we gain initial approvals for treatment of
patients with secondary AML and subsequent approvals for use in older 'de novo'
AML patients. With approvals in secondary AML alone, we could expect global peak
sales in the range of $440 to $580 million.
We continue to talk to potential licensing partners for AS1413. There is
interest in global and regional partnerships. However, we will only conclude a
deal or deals before phase III data if compelling terms are available.
AS1411 also approaching key results
We are enrolling patients into a phase IIb trial of AS1411 in AML, which builds
on positive findings from an earlier phase II trial in the same setting. We
recently expanded the geographical reach of the study to include India in
addition to sites already active in the U.S., South Korea, Taiwan, Australia and
New Zealand.
We expect to report headline findings from the phase IIb trial in the first half
of 2011. If these are positive, the next step will be a pivotal phase III trial
in AML, as well as consideration of opportunities for the drug in other cancer
settings. Clinical and non-clinical data suggest that AS1411 could have
application across a number of blood cancers and solid tumours.
DCAM programme progressing towards partnering
Our DCAMs (dendritic cell auto-immune modulators) are highly specific, small-
molecule inhibitors of wild-type Flt3 designed for oral treatment of auto-immune
conditions. Following positive results in animal models of inflammatory bowel
disease and rheumatoid arthritis, we are working towards establishing a
licensing partnership for further development of the programme.
Cash resources meet business needs
Our existing cash resources are anticipated to cover the needs of the business
until well after we report our critical trial data in the first half of calendar
2011.
Outlook
Our current focus is delivery of the clinical data for AS1413 and AS1411 and
preparation to ensure we can move rapidly to exploit positive outcomes from the
trials of either or both of these drugs.
Barry Price
Chairman
13.10.10 10:09
#663
bounce1
dann schlafe ich noch 6 Monate weiter...
...Marktpotential scheint bei erfolgreicher Phase III/Verpartnerung anscheinend vorhanden zu sein: ...
"Our forecasts based on this research indicate that peak global sales of AS1413 could reach $670 million per annum if we gain initial approvals for treatment of patients with secondary AML and subsequent approvals for use in older 'de novo' AML patients.
With approvals in secondary AML alone, we could expect global peak sales in the range of $440 to $580 million." ...
Und eine Verpartnerung könnte nach erfolgreichem Phase III auch in 6 Monaten anstehen....
We continue to talk to potential licensing partners for AS1413. There is interest in global and regional partnerships. However, we will only conclude a deal or deals before phase III data if compelling terms are available.
hoffentlich wird es was...ich drücke uns Allen die Daumen!
13.10.10 10:12
#664
silverfish
Sollte die Phase III
von AS1413 erfolgreich sein, dann müssen wir uns über die derzeitigen Kurse keine Gedanken mehr machen. Falls nicht, dann vermutlich auch nicht mehr lange über Antisoma. ;-)
13.10.10 10:16
#665
lamaro
genauso
sehe ich das auch...dann ist antisoma pleite und keiner interresiert sich mehr für den Laden.
13.10.10 11:48
#666
hoomer
Phase III
dann wollen wir mal das Beste hoffen. Wie von bounce1 bereits erwähnt, wäre scheinbar ein schönes Marktpotential vorhanden.
Ich kann (oder will) einfach nicht glauben, dass ein Unternehmen wie Antisoma, welches doch bereits einige Jahre existiert (1988), nun nur noch negative Testergebnisse vorlegen wird. Wenn sie wirklich so schlecht "arbeiten", wie hätten sie denn all die letzten Jahre überstehen sollen?
Uns bleibt nun nichts weiters übrig als abzuwarten.
Auf ein positives Testergebnis!!
Ich kann (oder will) einfach nicht glauben, dass ein Unternehmen wie Antisoma, welches doch bereits einige Jahre existiert (1988), nun nur noch negative Testergebnisse vorlegen wird. Wenn sie wirklich so schlecht "arbeiten", wie hätten sie denn all die letzten Jahre überstehen sollen?
Uns bleibt nun nichts weiters übrig als abzuwarten.
Auf ein positives Testergebnis!!
13.10.10 13:35
#667
lamaro
sie müssen
einen pharmariesen finden der einsteigt oder das präp kauft
pfizer novatis glaxo könnten sowas aus der portokasse zahlen
13.10.10 13:43
#668
kalleari
@hoomer
Ein paar minderwertige Sachen hatte Antisoma schon. Aber es fehlt der richtige Durchbruch. Letztes hoffnungsvolles Medikament war ein Flop und hat den Kurs runter gerissen. Es muss endlich mal wieder was Gutes aus der Pipeline kommen,
mfg
Kalle
mfg
Kalle
14.10.10 19:54
#670
silverfish
Wieso sollte sie,
stehen doch keine News an. Du kannst eigentlich eher froh sein, dass es nicht noch weiter runter geht. Das ist halt das Risiko, wenn man sich möglichst frueh positioniert. Es läuft ewig seitwärts und wenn die News dann kommen gehts oft schneller nach oben oder unten wie man reagieren kann.
15.10.10 21:20
#673
Fortunato69
denke
Es sind genügend aktien, die im augenblick mehr interesse auf sich lenken vorhanden. ich werde weiter kaufen !